About Mentor Capital
Mentor Capital targets warrant proceeds for operating cancer companies often like those in the Cancer Immunotherapy Index and to invest in those or related firms via stock purchase or acquisition. The company's advantage is to seek in depth medical science judgment to screen cancer breakthroughs for probable success well in advance of the FDA process. In the Mentor program, an identified cancer company enters into a Long-term Equity Funding Agreement with the company. The company receives cancer related shares that are held in escrow until the associated investment payable is retired. The cancer fighting company receives cash from warrant proceeds at an agreed upon fixed price. The mutually related funding contracts speed up payment to the cancer companies growing most quickly.
Want to inform investors similar to Mentor Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Mentor Capital News
Nov 22, 2022
PLANO, Texas–(BUSINESS WIRE)–Mentor Capital, Inc. (OTCQB: MNTR) announced 25% annualized sales growth to $7,472,367 for the trailing twelve months or $0.33 per share against a share price of $0.05 per share in its quarterly Form 10-Q filing for the third quarter ended September 30, 2022, filed with the Securities and Exchange Commission. During and subsequent […]
Mentor Capital Investments
Mentor Capital has made 27 investments. Their latest investment was in eShiksa as part of their Seed VC on March 3, 2019.
Mentor Capital Investments Activity
Unattributed - III
Pueblo West Organics
Unattributed - II
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.